Prostate Specific Antigen

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 45537 Experts worldwide ranked by ideXlab platform

William J. Catalona - One of the best experts on this subject based on the ideXlab platform.

  • A multicenter study of [-2]pro-Prostate Specific Antigen combined with Prostate Specific Antigen and free Prostate Specific Antigen for Prostate cancer detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen range
    The Journal of Urology, 2011
    Co-Authors: William J. Catalona, Martin G Sanda, Leonard S Marks, Kevin M. Slawin, Chris H Bangma, George G Klee, Stacy Loeb, Alan Wayne Partin, Dennis L. Broyles
    Abstract:

    Purpose: Prostate Specific Antigen and free Prostate Specific Antigen have limited Specificity to detect clinically significant, curable Prostate cancer, leading to unnecessary biopsy, and detection and treatment of some indolent tumors. Specificity to detect clinically significant Prostate cancer may be improved by [-2]pro-Prostate Specific Antigen. We evaluated [-2]pro-Prostate Specific Antigen, free Prostate Specific Antigen and Prostate Specific Antigen using the formula, ([-2]pro-Prostate Specific Antigen/free Prostate Specific Antigen × Prostate Specific Antigen1/2) to enhance Specificity to detect overall and high grade Prostate cancer.Materials and Methods: We enrolled 892 men with no history of Prostate cancer, normal rectal examination, Prostate Specific Antigen 2 to 10 ng/ml and 6-core or greater Prostate biopsy in a prospective multi-institutional trial. We examined the relationship of serum Prostate Specific Antigen, free-to-total Prostate Specific Antigen and the Prostate health index with b...

  • 2 proenzyme Prostate Specific Antigen is more accurate than total and free Prostate Specific Antigen in differentiating Prostate cancer from benign disease in a prospective Prostate cancer screening study
    The Journal of Urology, 2010
    Co-Authors: Christopher R Griffin, Stacy Loeb, Gustavo F Carvalhal, Donghui Kan, Nikola A Baumann, William J. Catalona
    Abstract:

    Purpose: Due to the limited Specificity of Prostate Specific Antigen for Prostate cancer screening, there is an ongoing search for adjunctive biomarkers. Retrospective studies have suggested that an isoform of proenzyme Prostate Specific Antigen called [-2]proenzyme Prostate Specific Antigen may enhance the Specificity of Prostate Specific Antigen based screening. We examined the usefulness of this isoform in a prospective Prostate cancer screening study.Materials and Methods: From a population of 2,034 men undergoing Prostate cancer screening we examined the relationship between the measurement of the [-2]isoform of proenzyme Prostate Specific Antigen (p2PSA) and Prostate cancer detection. Specifically we compared the usefulness of total Prostate Specific Antigen, the ratio of free-to-total Prostate Specific Antigen, the ratio of p2PSA-to-free Prostate Specific Antigen, and a formula combining Prostate Specific Antigen, free Prostate Specific Antigen and p2PSA (the Beckman Coulter Prostate health index o...

  • Prostate Specific Antigen Assay Standardization Bias Could Affect Clinical Decision Making
    The Journal of Urology, 2008
    Co-Authors: Stacy Loeb, Daniel Wan-yui Chan, Jack Maggiore, Dana M Mondo, Stephen D. Mikolajczyk, Christopher R Griffin, Lori J. Sokoll, William J. Catalona
    Abstract:

    Purpose: Although Prostate Specific Antigen is widely used to detect and manage Prostate cancer, many patients and physicians are unaware of which Prostate Specific Antigen assay is being used. Most commercial Prostate Specific Antigen assays are standardized to the WHO 90:10 standard or aligned with the original Hybritech® assay with potentially disparate results.Materials and Methods: A total of 1,916 men participated in a Prostate cancer screening study in 2007. On the day of collection Prostate Specific Antigen was tested from the same serum sample using the Access® (Hybritech standard) and ADVIA Centaur® (WHO 90:10 Prostate Specific Antigen standard) assays. We examined the differences between the 2 assays and the effect that this might have on clinical decisions.Results: Median Prostate Specific Antigen was 0.9 and 1.05 ng/ml for the Centaur and Access assays, respectively, representing a 17% difference. Mean Prostate Specific Antigen was 3.45 and 4.79 ng/ml, respectively, representing a 38% differe...

  • Prostate Specific Antigen Velocity in Men With Total Prostate Specific Antigen Less Than 4 ng/ml
    The Journal of Urology, 2007
    Co-Authors: Stacy Loeb, Robert B. Nadler, Xiaoying Yu, Kimberly A. Roehl, William J. Catalona
    Abstract:

    Purpose: A Prostate Specific Antigen velocity threshold of 0.75 ng/ml per year has commonly been used to distinguish men with Prostate cancer from those with benign Prostate conditions. In addition, a Prostate Specific Antigen velocity greater than 2 ng/ml per year has been linked to an increased Prostate cancer Specific mortality rate after radical Prostatectomy and after radiation therapy. However, both of these frequently cited thresholds were determined largely in groups of men with a Prostate Specific Antigen greater than 4 ng/ml.Materials and Methods: Of approximately 26,000 men who participated in a Prostate cancer screening study 22,019 had a Prostate Specific Antigen of 4 ng/ml or less. Of these men 501 were diagnosed with Prostate cancer and had sufficient data for a Prostate Specific Antigen velocity calculation. We performed univariate and multivariate analyses to compare cancer detection rates and performance characteristics using various Prostate Specific Antigen velocity thresholds in these...

  • The Association Between Total Prostate Specific Antigen Concentration and Prostate Specific Antigen Velocity
    The Journal of Urology, 2007
    Co-Authors: Xiaoying Yu, Stacy Loeb, Kimberly A. Roehl, William J. Catalona
    Abstract:

    Purpose: It has been previously demonstrated that a Prostate Specific Antigen velocity greater than 2 ng/ml per year is associated with reduced cancer Specific survival following radical Prostatectomy or external beam radiation. However, men with different initial Prostate Specific Antigen levels may be more or less likely to reach this Prostate Specific Antigen velocity threshold. Because Prostate Specific Antigen and Prostate Specific Antigen velocity contain much of the same predictive information, our objective was to further examine the relationship between them.Materials and Methods: From a large Prostate cancer screening study, serial Prostate Specific Antigen measurements were available for 13,276 men, including 1,851 with a negative digital rectal examination who underwent biopsy and 894 who were diagnosed with Prostate cancer. Prostate Specific Antigen velocity was calculated using simple linear regression of the Prostate Specific Antigen values from the year before diagnosis. ANOVA and the Krus...

Stephen J Freedland - One of the best experts on this subject based on the ideXlab platform.

  • Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index
    The Journal of Urology, 2018
    Co-Authors: Alireza Aminsharifi, Charlotte Bailey, Amanda De Hoedt, Stephen J Freedland, Lauren E. Howard, Yuan Wu, Thomas J Polascik
    Abstract:

    Purpose: We assessed the predictive value of Prostate Specific Antigen density to detect clinically significant Prostate cancer, defined as Prostate cancer grade group 2 or greater, in a series of men undergoing Prostate biopsy with Prostate Specific Antigen 4 to 10 ng/ml. We sought to define an optimum cutoff point for Prostate Specific Antigen density and assess how race and body mass index affects Prostate Specific Antigen density performance.Materials and Methods: We analyzed data on 2,162 men, of whom 56% were African American, with serum Prostate Specific Antigen 4 to 10 ng/ml who underwent Prostate biopsy. We compared the AUC between Prostate Specific Antigen and Prostate Specific Antigen density to predict clinically significant and any Prostate cancer vs no cancer. We calculated the negative predictive value of Prostate Specific Antigen density cutoff points ranging from 0.05 to 0.15 by every 0.01 step. We a priori defined the optimal cutoff point of Prostate Specific Antigen density as a negativ...

  • Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group
    The Journal of Urology, 2017
    Co-Authors: Anna E. Teeter, Kagan Griffin, Christopher L. Amling, William J. Aronson, Christopher J. Kane, Lauren E. Howard, Matthew R Cooperberg, Martha K. Terris, Stephen J Freedland
    Abstract:

    Purpose: Short Prostate Specific Antigen doubling time following recurrence after radical Prostatectomy portends a poor prognosis. Prostate Specific Antigen doubling time is traditionally calculated using Prostate Specific Antigen values 0.2 ng/ml or greater. We determined whether early Prostate Specific Antigen doubling time, calculated from the first detectable postoperative Prostate Specific Antigen up to and including the first recurrence value, correlates with Prostate cancer outcomes.Materials and Methods: Cox models were used to examine the association between early Prostate Specific Antigen doubling time and castration resistant Prostate cancer, metastases, and all cause and Prostate cancer Specific mortality in 674 men who underwent radical Prostatectomy between 1988 and 2014 and had a biochemical recurrence. Early Prostate Specific Antigen doubling time was examined as a log transformed continuous and a categorical variable.Results: After adjusting for multiple clinicopathological characteristic...

  • Association of Prostate-Specific Antigen doubling time and cancer in men undergoing repeat Prostate biopsy.
    International Journal of Urology, 2012
    Co-Authors: Daniel M. Moreira, Jean-alfred Thomas, Lionel L. Bañez, Madeline G. Mckeever, Leah Gerber, Stephen J Freedland
    Abstract:

    Objectives:  To analyze the association between Prostate-Specific Antigen doubling time with Prostate cancer risk and grade among men with Prostate-Specific Antigen levels ≥4.0 ng/mL undergoing repeat Prostate biopsy. Methods:  A total of 286 patients with Prostate-Specific Antigen ≥4 ng/mL and available Prostate-Specific Antigen doubling time data, who underwent repeat Prostate biopsy from 1996–2009, were included in this analysis. Prostate-Specific Antigen doubling time was divided into three groups: >9 years, 3–9 years and

  • Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time
    The Journal of Urology, 2008
    Co-Authors: Philip M. Arlen, Anthony V. D'amico, Fernando J Bianco, James L Gulley, William L. Dahut, Stephen J Freedland, William D Figg, Philip W Kantoff, Michael W Kattan
    Abstract:

    Purpose: Prostate Specific Antigen is a glycoprotein found almost exclusively in normal and neoplastic Prostate cells. Prostate Specific Antigen doubling time, or the change in Prostate Specific Antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with Prostate cancer. It is important to agree on definitions and values for the calculation of Prostate Specific Antigen doubling time, and to develop a common approach to outcome analysis and reporting.Materials and Methods: In September 2006 a conference was held at the National Cancer Institute in Bethesda, Maryland to define these parameters and develop guidelines for their use.Results: The Prostate Specific Antigen Working Group defined criteria regarding Prostate Specific Antigen doubling time including the calculation of Prostate Specific Antigen doubling time, evidence to support Prostate Specific Antigen doubling time as a predictive factor in the setting of biochemical recurrence and the use of prostat...

  • Prostate Specific Antigen Recurrence After Definitive Therapy
    The Journal of Urology, 2007
    Co-Authors: Stephen J Freedland, Judd W Moul
    Abstract:

    Purpose: We estimate that approximately 70,000 men yearly have Prostate Specific Antigen-only recurrence after failed definitive therapy. The ideal salvage therapy for these men is not clear. Treatment must be individualized based on the patient risk of progression, the likelihood of success and the risks involved with the therapy. However, to do so the risks and benefits of the various options must be known. Therefore, we provide a comprehensive overview of the natural history and treatment options for men with Prostate Specific Antigen-only recurrence.Materials and Methods: A literature review and overview of Prostate Specific Antigen-only recurrence after failed definitive therapy was done.Results: The natural history after Prostate Specific Antigen-only recurrence is long but variable. Median time from Prostate Specific Antigen-only recurrence after radical Prostatectomy to Prostate cancer death exceeds 16 years, although some men die within 1 year after PSA recurrence. Rapid Prostate Specific Antigen...

Stacy Loeb - One of the best experts on this subject based on the ideXlab platform.

  • A multicenter study of [-2]pro-Prostate Specific Antigen combined with Prostate Specific Antigen and free Prostate Specific Antigen for Prostate cancer detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen range
    The Journal of Urology, 2011
    Co-Authors: William J. Catalona, Martin G Sanda, Leonard S Marks, Kevin M. Slawin, Chris H Bangma, George G Klee, Stacy Loeb, Alan Wayne Partin, Dennis L. Broyles
    Abstract:

    Purpose: Prostate Specific Antigen and free Prostate Specific Antigen have limited Specificity to detect clinically significant, curable Prostate cancer, leading to unnecessary biopsy, and detection and treatment of some indolent tumors. Specificity to detect clinically significant Prostate cancer may be improved by [-2]pro-Prostate Specific Antigen. We evaluated [-2]pro-Prostate Specific Antigen, free Prostate Specific Antigen and Prostate Specific Antigen using the formula, ([-2]pro-Prostate Specific Antigen/free Prostate Specific Antigen × Prostate Specific Antigen1/2) to enhance Specificity to detect overall and high grade Prostate cancer.Materials and Methods: We enrolled 892 men with no history of Prostate cancer, normal rectal examination, Prostate Specific Antigen 2 to 10 ng/ml and 6-core or greater Prostate biopsy in a prospective multi-institutional trial. We examined the relationship of serum Prostate Specific Antigen, free-to-total Prostate Specific Antigen and the Prostate health index with b...

  • 2 proenzyme Prostate Specific Antigen is more accurate than total and free Prostate Specific Antigen in differentiating Prostate cancer from benign disease in a prospective Prostate cancer screening study
    The Journal of Urology, 2010
    Co-Authors: Christopher R Griffin, Stacy Loeb, Gustavo F Carvalhal, Donghui Kan, Nikola A Baumann, William J. Catalona
    Abstract:

    Purpose: Due to the limited Specificity of Prostate Specific Antigen for Prostate cancer screening, there is an ongoing search for adjunctive biomarkers. Retrospective studies have suggested that an isoform of proenzyme Prostate Specific Antigen called [-2]proenzyme Prostate Specific Antigen may enhance the Specificity of Prostate Specific Antigen based screening. We examined the usefulness of this isoform in a prospective Prostate cancer screening study.Materials and Methods: From a population of 2,034 men undergoing Prostate cancer screening we examined the relationship between the measurement of the [-2]isoform of proenzyme Prostate Specific Antigen (p2PSA) and Prostate cancer detection. Specifically we compared the usefulness of total Prostate Specific Antigen, the ratio of free-to-total Prostate Specific Antigen, the ratio of p2PSA-to-free Prostate Specific Antigen, and a formula combining Prostate Specific Antigen, free Prostate Specific Antigen and p2PSA (the Beckman Coulter Prostate health index o...

  • Single nucleotide polymorphisms and the likelihood of Prostate cancer at a given Prostate Specific Antigen level.
    The Journal of Urology, 2009
    Co-Authors: Stacy Loeb, Anna Kettermann, H Ballentine Carter, William B. Isaacs, Toshiko Tanaka, Luigi Ferrucci, Patrick C. Walsh, E. Jeffrey Metter
    Abstract:

    Purpose: Prostate Specific Antigen is used for Prostate cancer screening but its Specificity is limited. Specificity might be increased by considering genotype associated Prostate Specific Antigen levels.Materials and Methods: We examined associations between single nucleotide polymorphisms on chromosomes 10 and 19 (previously shown to be associated with Prostate Specific Antigen) with Prostate Specific Antigen and Prostate cancer in 505 men from the Baltimore Longitudinal Study of Aging.Results: In a model with age and date the risk ratio for Prostate cancer was 1.18 (95% CI 1.13–1.23) per unit increase in Prostate Specific Antigen. Including the interaction between alleles and Prostate Specific Antigen significantly altered the risk ratio for Prostate cancer (Cox proportional hazards p

  • Prostate Specific Antigen Testing Among the Elderly—When To Stop?
    The Journal of Urology, 2009
    Co-Authors: Edward M Schaeffer, Anna Kettermann, Bruce J. Trock, H Ballentine Carter, Luigi Ferrucci, Stacy Loeb, Patricia Landis, E. Jeffrey Metter
    Abstract:

    Purpose: Prostate Specific Antigen testing is common in the elderly despite evidence that older men without aggressive Prostate cancer are unlikely to benefit from diagnosis and treatment. We evaluated the relationship between Prostate Specific Antigen and the risk of aggressive Prostate cancer developing in men of various ages.Materials and Methods: This longitudinal cohort study consisted of 849 men (122 with and 727 without Prostate cancer) with serial Prostate Specific Antigen measurements participating in the Baltimore Longitudinal Study of Aging. The primary outcome measure was the proportion of men by Prostate Specific Antigen and age who died of Prostate cancer or in whom aggressive Prostate cancer developed (death from Prostate cancer, a Prostate Specific Antigen 20 ng/ml or greater, or Gleason score 8 or greater).Results: No participants between 75 and 80 years old with a Prostate Specific Antigen less than 3.0 ng/ml died of Prostate cancer. In contrast, men of all ages with a Prostate Specific ...

  • Prostate Specific Antigen Assay Standardization Bias Could Affect Clinical Decision Making
    The Journal of Urology, 2008
    Co-Authors: Stacy Loeb, Daniel Wan-yui Chan, Jack Maggiore, Dana M Mondo, Stephen D. Mikolajczyk, Christopher R Griffin, Lori J. Sokoll, William J. Catalona
    Abstract:

    Purpose: Although Prostate Specific Antigen is widely used to detect and manage Prostate cancer, many patients and physicians are unaware of which Prostate Specific Antigen assay is being used. Most commercial Prostate Specific Antigen assays are standardized to the WHO 90:10 standard or aligned with the original Hybritech® assay with potentially disparate results.Materials and Methods: A total of 1,916 men participated in a Prostate cancer screening study in 2007. On the day of collection Prostate Specific Antigen was tested from the same serum sample using the Access® (Hybritech standard) and ADVIA Centaur® (WHO 90:10 Prostate Specific Antigen standard) assays. We examined the differences between the 2 assays and the effect that this might have on clinical decisions.Results: Median Prostate Specific Antigen was 0.9 and 1.05 ng/ml for the Centaur and Access assays, respectively, representing a 17% difference. Mean Prostate Specific Antigen was 3.45 and 4.79 ng/ml, respectively, representing a 38% differe...

Akira Miyajima - One of the best experts on this subject based on the ideXlab platform.

  • Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen
    The Journal of Urology, 2017
    Co-Authors: Kazuhiro Matsumoto, Akari Komatsuda, Yoshinori Yanai, Eiji Kikuchi, Ryuichi Mizuno, Takeo Kosaka, Naoya Niwa, Akira Miyajima
    Abstract:

    Purpose: We analyzed long-term followup data after radical Prostatectomy to determine how long we should follow patients in whom the serum Prostate Specific Antigen level measured by an ultrasensitive assay was consistently low.Materials and Methods: We retrospectively reviewed clinicopathological data for 582 consecutive patients who underwent open or laparoscopic radical Prostatectomy between 1995 and 2004, excluding 4 patients who received adjuvant therapy. We stratified the patients according to Prostate Specific Antigen at 3 and 5 years after surgery, and examined subsequent biochemical recurrence (elevation of Prostate Specific Antigen to greater than 0.2 ng/ml) during followup. Mean followup was 9.7 years.Results: At 3 years after surgery Prostate Specific Antigen levels were measured by an ultrasensitive assay in 323 patients who had not experienced biochemical recurrence. In 187 patients with undetectable Prostate Specific Antigen levels (less than 0.01 ng/ml) the 10 and 15-year biochemical recur...

  • Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
    The Journal of urology, 2016
    Co-Authors: Kazuhiro Matsumoto, Akari Komatsuda, Yoshinori Yanai, Eiji Kikuchi, Ryuichi Mizuno, Takeo Kosaka, Naoya Niwa, Akira Miyajima
    Abstract:

    We analyzed long-term followup data after radical Prostatectomy to determine how long we should follow patients in whom the serum Prostate Specific Antigen level measured by an ultrasensitive assay was consistently low. We retrospectively reviewed clinicopathological data for 582 consecutive patients who underwent open or laparoscopic radical Prostatectomy between 1995 and 2004, excluding 4 patients who received adjuvant therapy. We stratified the patients according to Prostate Specific Antigen at 3 and 5 years after surgery, and examined subsequent biochemical recurrence (elevation of Prostate Specific Antigen to greater than 0.2 ng/ml) during followup. Mean followup was 9.7 years. At 3 years after surgery Prostate Specific Antigen levels were measured by an ultrasensitive assay in 323 patients who had not experienced biochemical recurrence. In 187 patients with undetectable Prostate Specific Antigen levels (less than 0.01 ng/ml) the 10 and 15-year biochemical recurrence-free survival rates were 99% and 96%, respectively. At 5 years after surgery Prostate Specific Antigen was measured in 315 patients by the ultrasensitive assay. In 162 patients with undetectable Prostate Specific Antigen levels the 10 and 15-year biochemical recurrence-free survival rates were both 100%. In this group the Prostate Specific Antigen level at last followup was less than 0.01 ng/ml in 132 patients, 0.01 to 0.03 ng/ml in 27 patients, and 0.06 ng/ml, 0.07 ng/ml and 0.11 ng/ml in 1 patient each. This long-term review indicates that if patients have continuously undetectable Prostate Specific Antigen levels by an ultrasensitive assay for 5 years, Prostate Specific Antigen monitoring can be stopped with an extremely low risk of subsequent biochemical recurrence. Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Kimberly A. Roehl - One of the best experts on this subject based on the ideXlab platform.

  • Prostate Specific Antigen Velocity in Men With Total Prostate Specific Antigen Less Than 4 ng/ml
    The Journal of Urology, 2007
    Co-Authors: Stacy Loeb, Robert B. Nadler, Xiaoying Yu, Kimberly A. Roehl, William J. Catalona
    Abstract:

    Purpose: A Prostate Specific Antigen velocity threshold of 0.75 ng/ml per year has commonly been used to distinguish men with Prostate cancer from those with benign Prostate conditions. In addition, a Prostate Specific Antigen velocity greater than 2 ng/ml per year has been linked to an increased Prostate cancer Specific mortality rate after radical Prostatectomy and after radiation therapy. However, both of these frequently cited thresholds were determined largely in groups of men with a Prostate Specific Antigen greater than 4 ng/ml.Materials and Methods: Of approximately 26,000 men who participated in a Prostate cancer screening study 22,019 had a Prostate Specific Antigen of 4 ng/ml or less. Of these men 501 were diagnosed with Prostate cancer and had sufficient data for a Prostate Specific Antigen velocity calculation. We performed univariate and multivariate analyses to compare cancer detection rates and performance characteristics using various Prostate Specific Antigen velocity thresholds in these...

  • The Association Between Total Prostate Specific Antigen Concentration and Prostate Specific Antigen Velocity
    The Journal of Urology, 2007
    Co-Authors: Xiaoying Yu, Stacy Loeb, Kimberly A. Roehl, William J. Catalona
    Abstract:

    Purpose: It has been previously demonstrated that a Prostate Specific Antigen velocity greater than 2 ng/ml per year is associated with reduced cancer Specific survival following radical Prostatectomy or external beam radiation. However, men with different initial Prostate Specific Antigen levels may be more or less likely to reach this Prostate Specific Antigen velocity threshold. Because Prostate Specific Antigen and Prostate Specific Antigen velocity contain much of the same predictive information, our objective was to further examine the relationship between them.Materials and Methods: From a large Prostate cancer screening study, serial Prostate Specific Antigen measurements were available for 13,276 men, including 1,851 with a negative digital rectal examination who underwent biopsy and 894 who were diagnosed with Prostate cancer. Prostate Specific Antigen velocity was calculated using simple linear regression of the Prostate Specific Antigen values from the year before diagnosis. ANOVA and the Krus...

  • Prostate Specific Antigen Velocity Threshold for Predicting Prostate Cancer in Young Men
    The Journal of Urology, 2007
    Co-Authors: Stacy Loeb, William J. Catalona, Kimberly A. Roehl, Robert B. Nadler
    Abstract:

    Purpose: Longitudinal changes in Prostate Specific Antigen are increasingly used to guide the recommendation for biopsy. Prostate Specific Antigen velocity 0.75 ng/ml yearly has been proposed to distinguish Prostate cancer from benign Prostate conditions. However, this threshold might be too high in young men with lower total Prostate Specific Antigen.Materials and Methods: In a large Prostate cancer screening study 6,844 men were 60 years or younger at study entry and Prostate Specific Antigen velocity calculation was possible. Of these men 346 (5%) were subsequently diagnosed with Prostate cancer and various Prostate Specific Antigen velocity thresholds were examined for prediction of Prostate cancer risk. Multivariate analysis was performed to determine whether Prostate Specific Antigen velocity is an independent predictor of Prostate cancer in men younger than 60 years.Results: Median Prostate Specific Antigen velocity was significantly higher in men who were later diagnosed with Prostate cancer than ...

  • Prostate Specific Antigen Density Correlates With Features of Prostate Cancer Aggressiveness
    The Journal of Urology, 2007
    Co-Authors: Shilajit D. Kundu, Brian K. Suarez, Jo Ann V Antenor, Xiaoying Yu, Kimberly A. Roehl, William J. Catalona
    Abstract:

    Purpose: An increased Prostate Specific Antigen density (serum Prostate Specific Antigen divided by Prostate volume) is an established parameter to help determine the need to perform Prostate biopsies. A man with a high Prostate Specific Antigen and a normal size Prostate gland is more likely to have cancer than a man with the same Prostate Specific Antigen and a large gland. Prostate Specific Antigen in relation to Prostate size should also reflect the volume of cancer in the gland. One group defined clinically unimportant Prostate cancer as tumor volume less than 0.5 cc, organ confined disease and Gleason less than 7. Another group noted that at the time of biopsy, a Prostate Specific Antigen density less than 0.15 ng/ml/cc combined with low risk clinical tumor features predicted insignificant cancer. There are limited published validating data on the association of Prostate Specific Antigen density with the criteria for Prostate cancer aggressiveness. We tested the association of Prostate Specific anti...

  • Comparison of Methods for Calculating Prostate Specific Antigen Velocity
    The Journal of Urology, 2006
    Co-Authors: Xiaoying Yu, Sara N Gashti, Stacy Loeb, Kimberly A. Roehl, William J. Catalona
    Abstract:

    Purpose: Prostate Specific Antigen velocity is frequently calculated using regression analysis of multiple Prostate Specific Antigen measurements during an interval of 18 to 24 months. It has been reported that the Prostate Specific Antigen velocity in the year before Prostate cancer diagnosis is associated with the cancer Specific mortality rate following radical Prostatectomy and radiation therapy. There are limited data comparing alternate methods of calculating Prostate Specific Antigen velocity. In this study we compared simple arithmetic Prostate Specific Antigen velocity calculations to the more complicated regression analysis using Prostate Specific Antigen measurements from varying intervals to determine whether the methods were interchangeable.Materials and Methods: From 2003 to 2005 a total of 540 men underwent radical retropubic Prostatectomy for localized Prostate cancer. Preoperative Prostate Specific Antigen velocity was calculated using arithmetic and linear regression methods during 12 an...

Related terms

Prostate Specific Antigen - 15 days free trial to Access Experts & Abstracts